Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance

Pemafibrate is a novel selective peroxisome proliferator‐activated receptor‐α modulator with potent triglyceride‐lowering and high‐density lipoprotein cholesterol‐raising effects. We showed that pemafibrate decreased the homeostatic model assessment for insulin resistance in patients with dyslipidemia. To investigate how pemafibrate improves insulin sensitivity, we used a hyperinsulinemic‐euglycemic clamp technique to determine the splanchnic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance.

• Publication year

  2018

• Venue

  Journal of Diabetes Investigation

• Publication date

  2018-04-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jdi.12845PMID 29603684PMCID 6215940
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.

  2017cited by this paper
• Adiponectin signaling and function in insulin target tissues

  2016cited by this paper
• Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.

  2016cited by this paper
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention

  2016cited by this paper
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

  2016cited by this paper
• Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver.

  2015cited by this paper
• The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.

  2014cited by this paper
• Bezafibrate improves insulin resistance evaluated using the glucose clamp technique in patients with type 2 diabetes mellitus: a small-scale clinical study

  2014cited by this paper
• ESC/EAS Guidelines for the Management of Dyslipidaemias

  2013cited by this paper
• Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

  2013cited by this paper
• Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

  2013cited by this paper
• Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

  2012cited by this paper
• Insulin Resistance and the Relationship of a Dyslipidemia to Coronary Heart Disease: The Framingham Heart Study

  2011cited by this paper
• Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

  2010cited by this paper
• Fibroblast growth factor 21: from pharmacology to physiology.

  2010cited by this paper
• Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity.

  2009cited by this paper
• The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man.

  2008cited by this paper
• Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus

  2007cited by this paper
• Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects.

  2007cited by this paper
• Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.

  2006cited by this paper
• PPARdelta regulates glucose metabolism and insulin sensitivity.

  2006cited by this paper
• PPARδ regulates glucose metabolism and insulin sensitivity

  2006cited by this paper
• Prevalence of primary non‐alcoholic fatty liver disease in a population‐based study and its association with biochemical and anthropometric measures

  2006cited by this paper
• Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients.

  2005cited by this paper
• Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.

  2004cited by this paper
• Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity.

  2004cited by this paper
• Insulin dose-response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes.

  2004cited by this paper
• Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

  2003cited by this paper
• Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome

  2003cited by this paper
• Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

  2001cited by this paper
• Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.

  2001cited by this paper
• Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.

  2001cited by this paper
• Association of nonalcoholic fatty liver disease with insulin resistance.

  1999cited by this paper
• Peroxisome proliferator-activated receptors: nuclear control of metabolism.

  1999cited by this paper
• High plasma free fatty acids decrease splanchnic glucose uptake in patients with non-insulin-dependent diabetes mellitus.

  1998cited by this paper
• PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

  1998cited by this paper
• Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group.

  1998cited by this paper
• Mechanism of action of fibrates on lipid and lipoprotein metabolism.

  1998cited by this paper
• Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM

  1997cited by this paper
• A noninvasive method to measure splanchnic glucose uptake after oral glucose administration.

  1995cited by this paper
• Effect of strict metabolic control on glucose handling by the liver and peripheral tissues in non-insulin-dependent diabetes mellitus.

  1994cited by this paper
• Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study.

  1992cited by this paper
• Effect of fatty acids on glucose production and utilization in man.

  1983cited by this paper
• Glucose clamp technique: a method for quantifying insulin secretion and resistance.

  1979cited by this paper

• Post-hoc analysis of a phase 2 randomized trial of pemafibrate in metabolic dysfunction-associated steatotic liver disease: associations with platelet count, liver stiffness, and spleen volume.

  2026cites this paper
• Long-Term Safety and Efficacy of Pemafibrate to Treat Hyperlipidemia: Post-marketing Surveillance Over a 24-Month Observation Period in Japan

  2025cites this paper
• Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and updated meta-analysis of randomized controlled trials

  2025cites this paper
• A new potent and selective peroxisome proliferator-activated receptor alpha partial agonist displays anti-steatotic effects In vitro and behaves as a safe hypolipidemic and hypoglycemic agent in a diabetic mouse model.

  2025cites this paper
• Managing hypertriglyceridemia for cardiovascular disease prevention: Lessons from the PROMINENT trial

  2024cites this paper
• Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia

  2024cites this paper
• Impact of pemafibrate on lipid profile and insulin resistance in hypertriglyceridemic patients with coronary artery disease and metabolic syndrome

  2024cites this paper
• Molecular mechanisms and therapeutic perspectives of peroxisome proliferator‐activated receptor α agonists in cardiovascular health and disease

  2023cites this paper
• Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia

  2023cites this paper
• Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review

  2023cites this paper
• Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis

  2023cites this paper
• Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome

  2023cites this paper
• PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo.

  2022cites this paper
• Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study

  2022cites this paper
• Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate

  2021cites this paper
• Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?

  2021cites this paper
• Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy

  2021cites this paper
• Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

  2021cites this paper
• Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

  2021cites this paper
• The Interplay between Non-Esterified Fatty Acids and Plasma Zinc and Its Influence on Thrombotic Risk in Obesity and Type 2 Diabetes

  2021cites this paper
• Fatty acids may influence insulin dynamics through modulation of albumin‐Zn2+ interactions

  2021cites this paper
• Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases

  2020cites this paper
• A novel selective PPARα modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms

  2020cites this paper
• Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate

  2019cites this paper
• Recent developments in pharmacotherapy for hypertriglyceridemia: what’s the current state of the art?

  2019cites this paper
• Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination

  2019cites this paper
• SPPARM alpha: the Lazarus effect.

  2019cites this paper
• Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes

  2019cites this paper
• The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

  2019cites this paper
• Is hypertriglyceridemia atherogenic?

  2019cites this paper
• Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases

  2019cites this paper
• Future perspectives of the pharmacological management of diabetic dyslipidemia

  2019cites this paper
• Pemafibrate tends to have a better efficacy in treating dyslipidemia than fenofibrate.

  2019cites this paper
• Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis

  2019cites this paper
• Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study

  2019cites this paper
• Benefits and risks of the treatment with fibrates––a comprehensive summary

  2018cites this paper
• Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy

  2018cites this paper
• Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia

  2017cites this paper
• E�cacy and safety of Pema�brate administration in patients with dyslipidemia: A Systematic Review and Updated Meta-analysis of Randomized Controlled Trials.

  year unknowncites this paper